Compugen Ltd (NAS:CGEN)
$ 1.6 -0.03 (-1.84%) Market Cap: 139.78 Mil Enterprise Value: 30.66 Mil PE Ratio: 54.41 PB Ratio: 2.42 GF Score: 52/100

Compugen Ltd at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 05:20PM GMT
Release Date Price: $5.97 (+0.84%)
Alethia Young
Cantor Fitzgerald, L.P. - Analyst

Hey, everybody, it's Alethea Young here. I cover large cap, small mid-cap biotech at Cantor. Very happy to have Compugen here with us. We have Anat Cohen-Dayag, who is the President and CEO -- Dr. Anat Cohen-Dayag, let me correct myself. Dr. Henry Adewoye, SVP and CMO, and Ari Krashin, who is the CFO and COO.

We will be doing a fireside chat. And I'm sure everybody will kind of take turns of answering different questions that come along the way. So I just wanted to maybe take a minute and just have Anat talk about the big picture story of Compugen and what kind of accomplishments you've seen over the past 12 months, which I think are a good amount, actually.

Anat Cohen;Dayag
Compugen Ltd. - President & CEO

Sure, thank you, Alethia, and thank you for inviting us to your conference. So Compugen is a therapeutic discovery and development company. We discover new drug targets, and we develop first-in-class drugs to address these drug targets. We are discovering new drug targets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot